Breaking News

Tesco Falls as Much as 11.8% After Saying Profit Overstated
Tweet TWEET

Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in Spinal Cord Injury at the 23rd International

Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in
Spinal Cord Injury at the 23rd International Symposium on the Autonomic
Nervous System

CHARLOTTE, N.C., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) today announced results from a study of
Northera™ (droxidopa) in hypotensive individuals with spinal cord injury at
the 23^rd International Symposium on the Autonomic Nervous System, which took
place October 31 through November 3, 2012 in Paradise Island, Bahamas.

The poster, titled "Blood Pressure Effect of Droxidopa in Hypotensive
Individuals with Spinal Cord Injury," (poster #62) highlighted results of a
clinical study designed to determine the blood pressure effect of escalating
doses of droxidopa (100 mg, 200 mg & 400 mg) during three laboratory visits in
hypotensive subjects (n=10) with spinal cord injury (SCI). The level of SCI
ranged from cervical to low thoracic lesions, all were chronically injured and
non-ambulatory and 8 were motor complete.

Subjects were hypotensive at baseline (systolic BP: 87±14 mmHg; diastolic BP:
54±8 mmHg), and baseline BP did not differ among the 3 visits.Upon supine
repositioning prior to drug administration, BP increased significantly (SBP:
101±11 mmHg; DBP: 62±7 mmHg; p<0.0001 versus seated baseline), regardless of
dose, droxidopa did not augment the increase in BP upon supine
repositioning.Seated BP was significantly increased from baseline after
droxidopa in a dose-dependent manner (100 mg: 94±14/61±8 mmHg; 200 mg:
99±15/62±9 mmHg; 400 mg: 106±16/58±9 mmHg; p<0.0001).Although the elevation
in seated BP was relatively modest, average 4-hour seated SBP & DBP were
significantly increased with 400 mg droxidopa compared to 100 mg (p<0.001) and
200 mg (p<0.05).

"These preliminary data indicate that droxidopa increases seated BP in a
dose-dependent manner without worsening supine increases in BP in hypotensive
persons with SCI, suggesting a greater normalization of pressure across
positional changes," said lead author Jill M. Wecht, Ed.D, Associate Professor
of Medicine and Rehabilitation Medicine, the Mount Sinai School of
Medicine."Increasing seated blood pressure is an important clinical outcome
in these individuals, because hypotension has been linked to deficits in
memory and attention processing in the general population and in individuals
with SCI. Further study of droxidopa is warranted in the SCI population."

About Northera

NORTHERA™ (droxidopa), the lead investigational agent in Chelsea Therapeutics'
pipeline, is currently in Phase III clinical trials for the treatment of
symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary
autonomic failure – a group of diseases that includes Parkinson's disease,
multiple system atrophy (MSA) and pure autonomic failure (PAF). Droxidopa is a
synthetic catecholamine that is directly converted to norepinephrine (NE) via
decarboxylation, resulting in increased levels of NE in the nervous system,
both centrally and peripherally.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a variety
of human diseases, including central nervous system disorders. Chelsea is
currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a
novel, late-stage, orally-active therapeutic agent for the treatment of
symptomatic neurogenic orthostatic hypotension in patients with primary
autonomic failure. For more information about the Company, visit
www.chelseatherapeutics.com.

This press release contains forward-looking statements regarding future
events. These statements are subject to risks and uncertainties that could
cause the actual events or results to differ materially. These include the
risk that the FDA will not accept any proposal regarding any trial or other
data to support Study 301 or any other study, including the primary endpoint;
the risk that we will not be able to resubmit the NDA for Northera and that
the FDA will not approve a resubmitted NDA; the risk that our resources will
not be sufficient to develop any study of Northera that will be acceptable to
the FDA; the risk that we cannot complete any additional study for Northera
without the need for additional capital; the risks and costs of drug
development and that such development may take longer or be more expensive
than anticipated; our need to raise additional operating capital in the
future; our reliance on our lead drug candidate droxidopa; risk of regulatory
approvals of droxidopa or our other drug candidates for additional
indications; reliance on collaborations and licenses; intellectual property
risks; our history of losses; competition; and market acceptance for our
products if any are approved for marketing.

CONTACT: Investors:
         Michelle Carroll / Susan Kim
         Argot Partners
         212-600-1902
         michelle@argotpartners.com
         susan@argotpartners.com
        
         Media:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Chelsea Therapeutics Logo
 
Press spacebar to pause and continue. Press esc to stop.